For investors
Mitral valve disease is the leading cause of heart failure in dogs, with no minimally invasive curative option currently available. Our company is introducing the first transcatheter mitral valve prosthesis (TMVP) designed specifically for dogs, delivered percutaneously via the jugular vein. It merges cutting-edge human interventional technologies with a tailored approach for dogs. Canival is a groundbreaking alternative to high-risk open surgery and surgical beating heart procedures.
This device has the potential to reshape the landscape of veterinary cardiology
Meeting a substantial unmet clinical need in a large, underserved market.
Leveraging the rising trend in high-quality, specialized pet healthcare.
Establishing a new category in interventional veterinary devices with attractive margins and significant procedural revenues.
Long-term potential for platform adaptation to other veterinary cardiac indications.
/
If you would like more
information
about the investment
Canival Medical Inc.
521 Fifth Avenue, 17th Floor
New York, NY 10175
